719 related articles for article (PubMed ID: 27893331)
1. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
3. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
5. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Ferrari R;
Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
[TBL] [Abstract][Full Text] [Related]
7. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Heck SL; Mecinaj A; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; Røsjø H; Steine K; Geisler J; Gulati G; Omland T
Circulation; 2021 Jun; 143(25):2431-2440. PubMed ID: 33993702
[TBL] [Abstract][Full Text] [Related]
9. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
13. [Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers].
Kanorskiĭ SG; Staritskiĭ AG; Bozhko AA
Kardiologiia; 2005; 45(3):31-5. PubMed ID: 15821705
[TBL] [Abstract][Full Text] [Related]
14. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
[TBL] [Abstract][Full Text] [Related]
15. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
16. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.
Narayan HK; Finkelman B; French B; Plappert T; Hyman D; Smith AM; Margulies KB; Ky B
Circulation; 2017 Apr; 135(15):1397-1412. PubMed ID: 28104715
[TBL] [Abstract][Full Text] [Related]
17. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
18. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction.
Di Lisi D; Leggio G; Vitale G; Arrotti S; Iacona R; Inciardi RM; Nobile D; Bonura F; Novo G; Russo A; Novo S
J Cardiovasc Med (Hagerstown); 2016 Apr; 17(4):270-5. PubMed ID: 25501904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
